ENDRA to merge with Noble Africa, rename to Noble Africa Inc.; Q2 net income $160K

ENDRA Life Sciences Inc.

Merger with Noble Africa to rename ENDRA to Noble Africa Inc.; close expected Q4 2026.
Private placement of ~$50M gross proceeds with institutional investors and ASP Isotopes, concurrent with merger close.
Q2 2026 net income $160K vs net loss $1.2M in Q2 2025; cash $1.7M, restricted cash $3.8M, digital asset treasury $1.9M.
Completed $3.8M private placement in May 2026; R&D expenses down 39%, sales & marketing down 92% YoY.
Operating expenses $1.5M vs $1.3M; includes $542K non-cash stock comp vs $89K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.